Webinar Recap: How to Design and Validate Multiplex Immunofluorescence Panels

Summary:

Multiplex immunofluorescence relies on a well-designed, validated antibody panel. Oliver Braubach, PhD, R&D Director, and Karen Kwarta, PhD, Product Manager, walked through how panels actually get built: what specificity, sensitivity, and reproducibility look like in practice, and how pre-validated VistaPlex^® kits, commercial pre-conjugated antibodies, and VistaFlex^™-labeled antibodies combine into one panel. If your experiments have ever stalled because the marker you need has no conjugated antibody, this session is for you.

Key takeaways

1. The CellScape XR workflow: stain, image, erase, repeat

The CellScape^® XR platform delivers high fidelity, flexible subcellular proteomics for rapid and quantitative spatial phenotyping. Sample prep uses standard histopathology methods. The slide is stained automatically with up to five fluorescently labeled antibodies at once, imaged, and the signal is removed by filtered photobleaching combined with the proprietary EpicIF solution. Repeat until every biomarker is imaged.

As Dr. Kwarta put it, “It’s as simple as stain, image, erase, repeat.”

Two design choices carry the whole thing. Direct immunofluorescence means no secondary antibodies or antibody modifications. Gentle EpicIF^™ signal removal works with virtually any organic dye, so the platform’s seven excitation and emission channels, spanning 425 to 750 nm, line up with the fluorophores antibody vendors already sell.

2. Panel development is iterative, and that is the point

Dr. Braubach and Dr. Kwarta described panel building as two parallel tracks. You screen and optimize individual antibodies while you draft how those antibodies will sit in the final stain plan. When a clone fails your quality threshold, you pick a different clone or fluorophore pairing, redraft, and go again.

Three properties decide whether an antibody makes the panel:

Property	What you are checking	How it is verified
Specificity	Correct regional and subcellular labeling	Tissue architecture, such as B cells aggregating in germinal centers, plus the expected cellular pattern: FOXP3 nuclear, Lamin B1 as a thin line around the nucleus, Granzyme B punctate in the cytosol
Sensitivity	Signal resolved cleanly over background	Signal ratio measurement across every kit and antibody, disclosed in VistaPlex validation reports
Reproducibility	Same result, different section, different site	Multi-site validation across serial sections, operators, and instruments

At 182 nm per pixel, the platform resolves plasma membranes, cytoplasmic labeling, nuclei, and nuclear envelopes, which is what makes subcellular pattern checking possible rather than theoretical.

3. The tissue matters as much as the antibody

This was one of the more useful cautions in the session. Tonsil scores beautifully across immune and architecture markers. Move to breast cancer and markers like CD56 or CD229 label inconsistently.

Dr. Braubach’s explanation: tumors change, and clones sometimes stop recognizing a target that is still present. “This is not because the antibody is bad,” he said. It is why multiple monoclonal and polyclonal options exist for the same target, and why you confirm regionally, confirm cellularly, and pick the right tissue for the antibody.

He also flagged something worth knowing before you compare vendor validation data. Ki-67 measured two ways gave two very different answers: a pixel-intensity calculation returned 24.5, while a segmentation-based calculation comparing the brightest and dimmest percentiles returned 278. Same marker, same tissue, different math. Compare methods, not just numbers.

4. Reproducibility is tested across sites, not just sections

Bruker Spatial Biology validates every antibody and every kit against multiple serial sections on multiple systems in different geographic locations, run by different operators.

A testis example ran three serial sections: two in St. Louis on separate instruments with separate operators, one in Hanover, Germany. The raw data came off the three systems remarkably similar, and cell counts by marker expression and by phenotype were analogous across all three. Those data are captured in the VistaPlex validation reports.

5. Three ways to build a panel, and you can mix them

Start with VistaPlex Multiplexing Assay Kits

Modular, validated panels covering spatial immune profiling, tissue architecture, and cell boundaries, for human and mouse FFPE and fresh frozen samples, imaging up to 36 immunophenotyping markers. Myeloid and macrophage kits are coming, along with neuro phenotyping, neurodegeneration, neuroinflammation, and neuroarchitecture kits.

Add commercial pre-conjugated

Because the platform’s seven channels match the most common fluorophores in vendor catalogs, adding a marker is largely plug and play. Titration is easy to automate: start at a 1:800 dilution, stain, image, skip the bleach, then repeat at lower dilutions on a single slide overnight. A CD45 example landed at 1:100. Directly conjugated antibodies typically optimize between 1:100 and 1:500.

Label your own with the VistaFlex portfolio antibody labeling kits, powered by Proteintech Group

For institutional clones or targets with no conjugated option, you label an unlabeled IgG with a CellScape-compatible fluorophore of your choosing, quench the excess, and pipette it straight into your existing assay. As little as one microgram of primary antibody, roughly ten minutes, in a test tube, no specialized equipment.

The sequence does not matter. VistaPlex kits, vendor conjugates, and VistaFlex-labeled antibodies can all run in the same panel, in any order.

6. Sample re-interrogation changes how you plan experiments

Dr. Braubach called this his favorite technical feature. Because the chemistry is gentle, a stained slide can go back into the fridge, wait while you analyze the data, and return to the instrument later. The imaging plane is registered automatically, so new markers land on the exact same cells.

In one colon cancer example, a first cycle produced clean beta-catenin and p53 staining. The sample sat for two months while the lab decided what to do next, then four more antibodies were added to the same imaging plane. That lets you run experiments incrementally and follow a hypothesis or validate new antibodies on a single specimen.

7. What this looks like in real labs

Inflammatory bowel disease (IBD) at Northwestern University

Parambir Dulai’s team uses VistaPlex spatial immune profiling and tissue architecture kits for large IBD cohort studies. Quantifying FOXP3 intensity rather than simply calling cells positive or negative revealed that FOXP3 expression is not binary. Re-running neighborhood analysis on FOXP3-negative, low, and high T cells revealed a widespread pre-inflammatory FOXP3-low neighborhood that standard analysis had missed.

Primary CNS lymphoma at the National University of Singapore

Whole transcriptome profiling on the GeoMx® Digital Spatial Profiler (DSP) platform flagged high macrophage density and metabolic signatures pointing to lipid-laden macrophages. The team validated macrophage presence on the CellScape platform using VistaPlex kits, then purchased ten additional antibodies including GPNMB and TREM2 and returned to re-stain the same slide. They found associations between lipid-laden macrophages, T cells, and Tregs that differed between drug responders and non-responders.

A 208-plex tumor microarray

Niclas Blessin and colleagues at University Hospital Schleswig-Holstein validated up to 208-plex immunofluorescence panels including both protein and RNA targets spanning tumor differentiation, immune phenotypes, checkpoint pathways, cell proliferation, signaling, metabolism, angiogenesis, and stemness markers to develop translational predictive and prognostic spatial-omics panels and AI-informed signatures across multiple solid tumor indications. Signal intensity stayed consistent whether a marker ran at the beginning of an experiment (position 21) or the end (position 103), with the total test extending across more than 50 stain and removal cycles.

Metabolic markers in skin squamous carcinoma

Six targets, PDK1, PGDH, LDHA, GLS, G6PD, and GLUT1, had no pre-conjugated options, so they were labeled in house with VistaFlex kits and spiked into an existing VistaPlex-based assay. The result was much improved stratification of epithelial cell phenotypes and metabolically defined neighborhoods the base panel did not resolve.

Your Questions Answered

How many VistaFlex-labeled antibodies can go in one cycle?

As many as your open channels allow, each in a different color, with blocking buffer applied before every cycle that includes one. The real limit is workflow, since labeled antibodies are prepared immediately before use. Six to ten per experiment is the practical recommendation.

Can VistaPlex kits, vendor antibodies, and VistaFlex-labeled antibodies run together?

Yes, and the order does not matter. Fill each open channel with whichever antibody fits, from any source, and add more later through re-interrogation.

How do you validate an antibody for multiplex immunofluorescence?

Validate each antibody for specificity, sensitivity, and reproducibility before incorporating it into a multiplex panel. Confirm specificity by checking that the antibody labels the expected tissue region and cellular or subcellular location, using an appropriate positive-control tissue. Assess sensitivity by measuring how clearly the signal can be resolved above background, and optimize the antibody concentration through titration. Finally, confirm reproducibility across serial tissue sections and, when possible, across different instruments, operators, or sites. Once individual antibodies meet these criteria, they can be tested together in the full multiplex panel.

How do I know an antibody is specific enough for a multiplex panel?

Check two levels. Regionally, the antibody should label targets where tissue architecture says they belong, such as B cells in germinal centers. Cellularly, the pattern should match the biology: nuclear for FOXP3, a thin envelope line for Lamin B1, punctate cytosolic for Granzyme B. Confirm both in the tissue you plan to study.

How long can I store antigen-retrieved FFPE sections in storage buffer?

Testing supports at least six months for FFPE sections in storage buffer, with the experiment still running successfully afterward. Fresh frozen tissue degrades faster, so plan for one to two months and keep handling sterile. Best data always comes from freshly cut tissue.

Should I optimize a panel on whole sections or a TMA?

Both, in that order. Start with a whole section of a tissue you know expresses your targets, such as tonsil or spleen for an immune panel, so you have a positive control. Move to a multi-tissue array, then your TMA. Always include a control tissue on the TMA slide.

What if my target has no fluorophore-conjugated antibody available?

Label it yourself using the VistaFlex portfolio antibody labeling kits. One to two micrograms and about ten minutes gets you a CellScape-compatible antibody that drops into a VistaPlex or custom panel. This also makes clone screening cheap: label several candidates, test them, then buy the winner pre-conjugated.